

## RECENT PUBLICATIONS:

Precision Nanomedicine, 2019 January; Vol. 2, Issue 1

(in progress)

[Precision nanomedicine in atherosclerosis therapy: how far are we from reality?](#)

Wong YS, Bertrand C, Venkatraman SS, Precision nanomedicine in atherosclerosis therapy: how far are we from reality? Prec. Nanomed. 2019 Jan;2(1):226-241. <https://doi.org/10.33218.pnmano182018.1> (Accepted review)

[Nanotherapy Targeting NF-kappaB Attenuates Acute Pain After Joint Injury.](#)

Communication

Yan H, Duan X, Collins KH, Springer LE., Guilak FE, Wickline SA, M. Farooq Rai F, Pan H, Pham CTN, Prec. Nanomed. 2019 Jan;2(1):223-226

[Simultaneous release of dual drugs from polymer nano-implant inhibits recurrence in glioblastoma spheroids](#)

Research article

Devassy G, Ramachandran R, Jeena K, Junnuthula VR, Gopinatha VK, Manju CA, Manohar M, Nair SV, Raghavan SC, and Koyakutty M, Prec. Nanomed. 2019 Jan;2(1):211-222

Precision Nanomedicine, 2018 October; Vol. 1, Issue 3

FEATURED RESEARCH ARTICLE

**BASIC RESEARCH**

[Liposomal formulation of polyacrylate-peptide conjugate as a new vaccine candidate against cervical cancer.](#)

Khongkow M, Liu TY, Bartlett S, Hussein WM, Nevagi R, Jia ZF, Monteiro MJ, Wells J, Ruktanonchai UR, Skwarczynski M, Toth I, Prec. Nanomed. 2018 Oct;1(3):186-196.

In this study, the authors describe the improvement of vaccine delivery *via* using a polymer-based delivery system. Authors demonstrate that the combination of polymer-based and liposome delivery systems may be effective without the use of additional adjuvant and with just a single-dose immunization.

RESEARCH ARTICLES

**POTENTIAL CLINICAL SIGNIFICANCE**

[Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin.](#)

Krausz AE, Adler BL, Makdisi J, Schairer D, Rosen J, Landriscina A, Navati M, Alfieri A, Friedman JM, Nosanchuk JD, Rodriguez-Gabin A, Ye KQ, McDaid HM, Friedman AJ, Prec. Nanomed. 2018 Oct;1(3):172-185.

The treatment of triple-negative breast cancer is often difficult due to frequent resistance to doxorubicin. Using different nano-formulations based on sol-gel technology to encapsulate doxorubicin, the authors here showed enhanced dose-response metrics and tumor cell kill of these cancer cells due to an increased drug accumulation in the local tumor environment.

**BASIC RESEARCH**

[Specific Molecular Recognition as a Strategy to Delineate Tumor Margin Using Topically Applied Fluorescence Embedded Nanoparticles.](#)

Barton S, Li B, Siuta M, Janve VA, Song J, Holt CM, Tomono T, Ukawa M, Kumagai H, Tobita E, Wilson K, Sakuma S, Pham W. Prec. Nanomed. 2018 Oct;1(3):197-210.

The ability to delineate the tumor accurately during operation is important to ensure all tumor cells are resected. Here, the authors describe the development of a multimodal imaging probe using nanospheres to target epithelial cells of pancreatic cancer. The specificity to target only tumor cells was clearly shown in both in-vitro and in-vivo experiments.

**BASIC RESEARCH**

[Plasma samples from mouse strains and humans demonstrate different susceptibilities to complement activation.](#)

Neun BW, Szénási G, Szebeni J, Dobrovolskaia M., Prec. Nanomed. 2018 Oct;1(3):211-220.

The authors describe the importance of mouse strain selection for in vitro complement activation analysis addressing also the existence of inter- and intraspecies variability.

Precision Nanomedicine, 2018 July; Vol. 1, Issue 2

FEATURED RESEARCH ARTICLE

**BASIC RESEARCH**

[Cellular Trafficking of Sn-2 Phosphatidylcholine Prodrugs Studied with Fluorescence Lifetime Imaging and Super-resolution Microscopy;](#)

Maji D, Lu J, Sarder P, Schmieder AH, Cui G, Yang X, Pan D, Lew MD, Achilefu S, Lanza GM. Prec. Nanomed. 2018 July;1(2):127-145.

PERSPECTIVE

**PERSPECTIVE**

[Skin Biosensing and Bioanalysis: What the Future Holds;](#) Ng KW, Moghimi SM. Prec. Nanomed. 2018 July;1(2):124-127.

REVIEW

**BASIC RESEARCH**

[A Coming Era of Precision Diagnostics Based on Nano-assisted Mass Spectrometry;](#) Li RX, Gurav DD, Wan JJ, Qian K. Prec. Nanomed. 2018 July;1(2):162-172.

RESEARCH ARTICLES

**Rational Design of a siRNA Delivery System: ALOX5 and Cancer Stem Cells as Therapeutic Targets**, Rafael D, Andrade F, Montero S, Gener P, Seras-Franzoso J, Martínez F, González P, Florindo H, Arango D, Sayós J, Abasolo I, Videira M, Schwartz Jr. S. Prec. Nanomed. 2018 July;1(2):86-105. **BASIC RESEARCH**

**Lysozyme transport to the brain by Liposomes**; Nordling-David MM, Rachmin E, Ety Grad E, Golomb G, Prec. Nanomed. 2018 July;1(2):146-161. **BASIC RESEARCH**

**Retinal Multipotent Stem-Cell Derived “MiEye” Spheroid 3D Culture Model for Preclinical Screening of Non-viral Gene Delivery Systems**; Chen DW, Foldvari M. Prec. Nanomed. 2018 July;1(2):106-123. **POTENTIAL CLINICAL SIGNIFICANCE**

Precision Nanomedicine, 2018 April; Vol. 1, Issue 1

EDITORIALS

**The Story of Precision Nanomedicine – the Journal**; Lajos P Balogh, Prec. Nanomed. 2018, Apr; 1(1):1-4. **COMMENTARY**

**Balancing Interests of Science, Scientists, and the Publishing Business**; Lajos P Balogh, Prec. Nanomed. 2018, Apr; 1(1):5-14. **OPINION**

**Improving Innovation in Nano-Healthcare Funding**, Mike Eaton, Prec. Nanomed. 2018 Apr; 1(1):15-17. **OPINION**

FEATURED RESEARCH ARTICLE

**Immunocompatibility of Rad-PC-Rad liposomes in vitro, based on human complement activation and cytokine release**; Matviyukiv S, Buscema M, Gerganova G, Mészáros T, Kozma GT, Mettal U, Neuhaus F, Ishikawa T, Szebeni J, Zumbuehl A, Müller B. Prec. Nanomed. 2018 Apr;1(1):43-62. **BASIC RESEARCH**

COMMUNICATION

**Discrepancies in the in vitro and in vivo role of scavenger receptors in clearance of nanoparticles by Kupffer cells**; Wang G, Groman E, Simberg D. Prec. Nanomed. 2018 Apr;1(1):76-85. **BASIC RESEARCH**

REVIEWS

**Origins to Outcomes: A Role for Extracellular Vesicles in Precision Medicine**; Savage, J, Maguire, CM, Prina-Mello A. Prec. Nanomed. 2018, Apr; 1(1):18-42. **PERSPECTIVE**

**A porcine model of complement activation-related pseudoallergy to nanopharmaceuticals: Pros and cons of translation to a preclinical safety test**; Szebeni J, Bedőcs P, Dézsi L, Urbanics R. Prec. Nanomed. 2018 Apr;1(1):63-75. **POTENTIAL CLINICAL SIGNIFICANCE**